Clinical Trials at MPTC
We are dedicated to advancing treatment options for patients battling cancer. MPTC will play a vital role in the advancement of radiation oncology.
Every patient treated at MPTC has access to a clinical trial. Read on to learn more about the trials we have available:
- NRG BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score (DEBRA) [Sponsor: NRG Oncology] PI: Sarah McAvoy, MD
- CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer [Sponsor: Canadian Cancer Trials Group] PI: Sarah McAvoy, MD
- GCCC 2563 PCG BRE009: Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO) [Sponsor: Proton Collaborative Group] PI: Elizabeth Nichols, MD
- NRG CC015: (HEAL-ABC): A study to examine mindfulness training to improve mental health and well-being in younger breast cancer survivors [Sponsor: NRG Oncology] PI: P. Reed McDonagh, III, MD, PhD
- GCC 1876: Tumor Bed Boost using a Breast Specific Radiosurgery Device, The GammaPodTM: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram; [Sponsor: University of Maryland, Baltimore] PI: Elizabeth Nichols, MD
- GCC 19140: Pilot Study of Laser Interstitial Thermal Therapy Followed by Hypofractionated Radiation Therapy for Treatment of Recurrent Gliomas [Sponsor: U. Maryland] PI: Mark V. Mishra, MD
- GCC20138: Laser Interstitial Thermal Therapy Followed by Hypofractionated Radiation Therapy for Treatment of Newly Diagnoses High-Grade Gliomas [Sponsor: U. Maryland] PI: Mark V. Mishra, MD
- GCC 2415: REMASTer: REcurrent brain Metastases After SRS Trial [Sponsor: Monteris Medical] PI: Mark V. Mishra, MD
- NRG CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer [Sponsor: NRG Oncology] PI: Mark V. Mishra, MD
- NRG BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases [Sponsor: NRG Oncology]
- NRG BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (fSRS) For Intact Brain Metastases [Sponsor: NRG Oncology] PI: Mark V. Mishra, MD
- GCC 1886: Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine with Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer [Sponsor: University of Maryland, Baltimore] PI: Jason Molitoris, MD, PhD
- GCC 2431: A pilot study of chemoimmunotherapy combined with hyperthermia and spatially-fractionated radiotherapy in advanced biliary tract cancer [Sponsor: University of Maryland, Baltimore] PI: Jason Molitoris, MD, PhD
- GCC 1944: A Randomized Phase III Trial of Two Standard Dose Fractionation Regimens for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer [Sponsor: Kara Romano, MD] PI: Sarah McAvoy, MD
- GCCC 2578: Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries [Sponsor: University of Maryland, Baltimore] PI: Elizabeth Nichols, MD
- NRG HN009: Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck [Sponsor: NRG] PI: Matthew Ferris, MD
- GCC 2380: A Single Arm Phase II Trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs based on Residual Circulating Tumor DNA Levels (SAVAL) [Sponsor: Dana-Farber Cancer Institute] PI: Jason Molitoris, MD
- EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features [Sponsor: National Cancer Institute (NCI)] PI: Matthew Ferris, MD
- GCC 2497: A Phase I, Single-Arm, Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NeoRADjuvant Trial). [Sponsor: University of Maryland, Baltimore] PI: Matthew Ferris
- GCC 1669: Pediatric Proton Consortium Registry: Registry for pediatric patients treated with proton RT [Sponsor: Massachusetts General Hospital] PI: Young Kwok, MD
- GCC 2032: Phase 1 Feasibility Study of Strength Training with Androgen Deprivation and Proton Therapy for Intermediate and High Risk Prostate Cancer [Sponsor: University of Maryland] PI: Matthew Ferris, MD
- GCC 21136: Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial [Sponsor: University of Maryland] PI: Phuoc Tran, MD
- GCC 23100: A randomized trial of high-risK metachroNous oligometastatIc prostate cancer with hiGh-risk mutations witH meTastasiS directed therapy and niraparib/abiraterone acetate and prednisone (KNIGHTS) [Sponsor: University of Maryland] PI: Jason Molitoris, MD
- NRG GU013: The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer [Sponsor: NRG Oncology] PI: Melissa Vyfhuis, MD, PhD
- GCC 1552: PCG Registry Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy [Sponsor: Proton Collaborative Group] PI: Mark V. Mishra, MD
- GCC 2442: Phase I Feasibility and Single Arm Pilot of Serious Illness Conversation Guide in Patient and Intimate Partner Dyads Living with Advanced Cancer [Sponsor: University of Maryland, Baltimore] PI: Martha Francis
- GCC 2494: Practical clinical interventions to help improve cancer care for patients who live in food priority areas (FPAs) or food deserts [Sponsor: University of Maryland, Baltimore] PI: Melissa Vyfhuis, MD, PhD
- NRG CC014: Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases (PREEMPT) [Sponsor: NRG Oncology] PI: Sarah McAvoy, MD
If you're interested in participating in a clinical trial, please call (410) 369-5351 to check on availability or speak with your physician during your consultation.
Request a Consultation
At Maryland Proton Treatment Center, we’re committed to helping you navigate your cancer treatment journey with clarity and confidence.
After a diagnosis, it’s normal to have questions, and our team is here to answer every one.
If you’re wondering if proton therapy the right option for you, request a consultation by completing the short form below. It takes just 3 minutes.
Once submitted, a front desk team member will call you within two business days: (410-442-6486).
